Treatment with IFN-γ increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides

Journal of Dermatological Science

Volumn 38, Issue 3, 2005, Pages 189-195

  Hino, Ryosuke ^a   Shimauchi, Takatoshi ^a   Tokura, Yoshiki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Chemokine; Cutaneous T cell lymphoma; Interferon ; Mycosis fungoides

Indexed keywords

BIOGAMMA; CXCL9 CHEMOKINE; MACROPHAGE DERIVED CHEMOKINE; RECOMBINANT GAMMA INTERFERON; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALE; MYCOSIS FUNGOIDES; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

AGED; CHEMOKINES; CHEMOKINES, CC; CHEMOKINES, CXC; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PHENOTYPE; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 20344381283     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2005.01.005     Document Type: Article

References (22)

1. R. Willemze, H. Kerl, and W. Sterry EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer Blood 90 1997 354 371
2. B.R. Vowels, S.R. Lessin, M. Cassin, C. Jaworsky, B. Benoit, and J.T. Wolfe Th2 cytokine mRNA expression in skin in cutaneous T cell lymphoma J Invest Dermatol 103 1994 669 673
3. L.A. Noorduyn, R.C. Beljaards, and S.T. Pals Differential expression of the HECA-452 antigen (cutaneous lymphocyte-associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas Histopathology 21 1992 59 64
4. C.L. Berger, N. Wang, I. Christensen, J. Longley, P. Heald, and R.L. Edelson The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens J Invest Dermatol 107 1996 392 397
5. N. Seo, Y. Tokura, K. Matsumoto, F. Furukawa, and M. Takigawa Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-γ (IFN-γ) and IL-12 and fluctuations in association with disease activity Clin Exp Immunol 112 1998 403 409
6. K. Ishihara, S. Ikeda, S. Mori, H. Urabe, and R. Arao Phase II study of recombinant human interferon γ (SUN4800) for cutaneous malignancies Nishinihon Hifuka 51 1989 766 775
7. E.H. Kaplan, S.T. Rosen, D.B. Norris, H.H. Roenigk Jr., S.R. Saks, and P.A. Bunn Jr. Phase II study of recombinant human interferon γ for treatment of cutaneous T-cell lymphoma J Natl Cancer Inst 82 1990 208 212
8. D. Rossi, and A. Zlotnic The biology of chemokines and their receptors Annu Rev Immunol 18 2000 217 242
9. M. Kobayashi, T. Shimauchi, R. Hino, and Y. Tokura Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors Cell Immunol 228 2004 27 33
10. F. Sallusto, D. Lenig, C.R. Mackay, and A. Lanzavecchia Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes J Exp Med 187 1998 875 883
11. K. Ferenczi, R.C. Fuhlbrigge, J. Pinkus, G.S. Pinkus, and T.S. Kupper Increased CCR4 expression in cutaneous T cell lymphoma J Invest Dermatol 19 2002 1405 1410
12. T. Kakinuma, M. Sugaya, K. Nakamura, F. Kaneko, M. Wakugawa, and K. Matsushima Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides J Am Acad Dermatol 48 2003 23 30
13. E. Papadavid, J. Economidou, A. Psarra, V. Kapsimali, V. Mantzana, and C. Antoniou The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome Br J Dermatol 148 2003 709 718
14. J.L. Sanches, and A.B. Ackerman The patch stage of mycosis fungoides Criteria for histologic diagnosis Am J Dermatopathol 1 1979 5 26
15. P.E. Shapiro, and F.J. Pinto The histollogic spectrum of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes Am J Surg Pathol 18 1994 645 667
16. K. Ikuta, T. Ogura, A. Shimizu, and T. Honjo Low frequency of somatic mutation in beta-chain variable region genes of human T-cell receptors Proc Natl Acad Sci USA 82 1985 7701 7705
17. H. Yagi, Y. Tokura, F. Furukawa, and M. Takigawa CD7-positive Sézary syndrome with a Th1 cytokine profile J Am Acad Dermatol 34 1996 368 374
18. T. Tsuda, M. Tohyama, K. Yamasaki, Y. Shirakata, Y. Yahata, and S. Tokumaru Lack of evidence for TARC/CCL17 production by normal human keratinocytes in vitro J Dermatol Sci 31 2003 37 42
19. T. Kakinuma, K. Nakamura, M. Wakugawa, S. Yano, H. Saeki, and H. Torii IL-4, but not IL-13, modulates TARC (thymus and activation-regulated chemokine)/CCL17 and IP-10 (interferon-induced protein of 10 kDA)/CXCL10 release by TNF-α and IFN-γ in HaCaT cell line Cytokine 20 2002 1 6
20. T. Xiao, S. Kagami, H. Saeki, M. Sugaya, T. Kakinuma, and H. Fujita Both IL-4 and IL-13 inhibit the TNF-alpha and IFN-gamma enhanced MDC production in a human keratinocyte cell line, HaCaT cells J Dermatol Sci 31 2003 111 117
21. S. Mahalingam, G. Chaudhri, C.L. Tan, A. John, P.S. Foster, and G. Karupiah Transcription of the interferon γ (IFN-γ)-inducible chemokine Mig in IFN-γ-deficient mice J Biol Chem 276 2001 7568 7574
22. M.T. Villagomez, S.J. Bae, I. Ogawa, M. Takenaka, and I. Katayama Tumour necrosis factor-α but not interferon-γ is the main inducer of inducible protein-10 in skin fibroblasts from patients with atopic dermatitis Br J Dermatol 150 2004 910 916